Previous research has indicated that 12–65% of GC patients exhibit upregulated PD‐L1 expression, which is closely linked to a poor prognosis.[19, 20] As a “cold tumor” with a poor immunogenicity, GC renders it difficult for immune checkpoint inhibitors to effectively block immune escape, resulting in a limited efficacy for immune checkpoint blockade therapy.[21, 22] Therefore, there is an urgent requirement to the development of a comprehensive therapeutic strategy that can both kill tumors and convert “cold tumors” into “hot tumors.” Here, CD274 is linked to gastric cancer.